Primary analysis of STARTAR: A phase 2 salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP)

Tian Zhang,Lauren Howard,Bridget F. Koontz,Scott T. Tagawa,Himanshu Nagar,Rhonda L. Bitting,Bart Frizzell,Luke T. Nordquist,Julia Rasmussen,Carolyn Winters,Colleen Riggan,Marco Reyes-Martinez,Catrin Davies,Steven Gray, Carly Newman, Escarleth Fernandez,Michael Roger Harrison,Daniel J. George,Yuan Wu,Andrew J. Armstrong

JOURNAL OF CLINICAL ONCOLOGY（2023）

引用 0|浏览20

暂无评分

摘要

90Background: ADT with salvage RT improves survival for men with PSA recurrence after RP. Current standard duration of ADT for high risk PSA recurrence is up to 2 years with RT; therefore shortenin...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要